Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POSEIDON
2017-000920-81Phase 3Unknown
- Sponsor
- AstraZeneca
- Start
- May 2017
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of durvalumab and tremelimumab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by AstraZeneca. Primary endpoints: Progression-free survival and Overall survival. Status: unknown.
02
Drugs
durvalumabtremelimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2017-000920-81.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000920-81.